title: Pasireotide: a novel treatment for patients with acromegaly.
abstract: Morbidity and mortality rates in patients with active acromegaly are higher than the general population. Adequate biochemical control restores mortality to normal rates. Now, medical therapy has an increasingly important role in the treatment of patients with acromegaly. Somatostatin receptor ligands (SRLs) are considered the standard medical therapy, either after surgery or as a first-line therapy when surgery is deemed ineffective or is contraindicated. Overall, octreotide and lanreotide are first-generation SRLs and are effective in ~20%-70% of patients. Pegvisomant, a growth hormone receptor antagonist, controls insulin-like growth factor 1 in 65%-90% of cases. Consequently, a subset of patients (nonresponders) requires other treatment options. Drug combination therapy offers the potential for more efficacious disease control. However, the development of new medical therapies remains essential. Here, emphasis is placed on new medical therapies to control acromegaly. There is a focus on pasireotide long-acting release (LAR) (Signifor LAR®), which was approved in 2014 by the US Food and Drug Administration and the European Medicine Agency for the treatment of acromegaly. Pasireotide LAR is a long-acting somatostatin multireceptor ligand. In a Phase III clinical trial in patients with acromegaly (naïve to medical therapy or uncontrolled on a maximum dose of first-generation SRLs), 40 and 60 mg of intramuscular pasireotide LAR achieved better biochemical disease control than octreotide LAR, and tumor shrinkage was noted in both pasireotide groups. Pasireotide LAR tolerability was similar to other SRLs, except for a greater frequency and degree of hyperglycemia and diabetes mellitus. Baseline glucose may predict hyperglycemia occurrence after treatment, and careful monitoring of glycemic status and appropriate treatment is required. A precise definition of patients with acromegaly who will derive the greatest therapeutic benefit from pasireotide LAR remains to be established. Lastly, novel therapies and new potential delivery modalities (oral octreotide) are summarized.
authors.affiliation: Department of Endocrinology and Metabolism, Neuroendocrinology Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
authors.forename: Daniel
authors.initials: D
authors.lastname: Cuevas-Ramos
authors.affiliation: Department of Medicine (Endocrinology), Portland, OR, USA; Department of Neurological Surgery, Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Fleseriu
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D015282:Octreotide; D013004:Somatostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D003692:Delayed-Action Preparations; D013004:Somatostatin; C517782:pasireotide; D015282:Octreotide
keywords: emerging treatments; growth hormone; insulin-like growth factor 1; pasireotide; somatostatin analogs; somatostatin receptor ligand
references.citation: Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):321-9
references.pmid: 23807604
references.citation: Endocr Metab Immune Disord Drug Targets. 2014;14(3):169-81
references.pmid: 24915854
references.citation: J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75
references.pmid: 16968795
references.citation: J Clin Endocrinol Metab. 2004 Feb;89(2):638-45
references.pmid: 14764775
references.citation: Clin Endocrinol (Oxf). 2010 Feb;72(2):203-8
references.pmid: 19473180
references.citation: Neuroendocrinology. 2016;103(1):66-74
references.pmid: 25661647
references.citation: J Mol Endocrinol. 2014 Jun;52(3):R223-40
references.pmid: 24647046
references.citation: J Clin Endocrinol Metab. 2007 Oct;92(10):3854-60
references.pmid: 17652220
references.citation: Pituitary. 2015 Dec;18(6):803-7
references.pmid: 25893613
references.citation: J Clin Endocrinol Metab. 2013 Oct;98(10):4047-54
references.pmid: 23969184
references.citation: Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):639-57
references.pmid: 18971124
references.citation: J Clin Pharmacol. 2014 Nov;54(11):1308-17
references.pmid: 24800725
references.citation: J Clin Endocrinol Metab. 2013 Aug;98(8):3446-53
references.pmid: 23733372
references.citation: J Clin Endocrinol Metab. 2001 Jul;86(7):2929-34
references.pmid: 11443145
references.citation: Nat Rev Endocrinol. 2011 May;7(5):257-66
references.pmid: 21423242
references.citation: J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
references.pmid: 25356808
references.citation: Trends Endocrinol Metab. 2010 Mar;21(3):123-33
references.pmid: 20149677
references.citation: J Clin Endocrinol Metab. 2012 Jul;97(7):2362-9
references.pmid: 22539587
references.citation: Trends Endocrinol Metab. 2013 May;24(5):238-46
references.pmid: 23270713
references.citation: J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9
references.pmid: 20410233
references.citation: Endocr Rev. 2004 Feb;25(1):102-52
references.pmid: 14769829
references.citation: J Clin Endocrinol Metab. 2012 May;97(5):1589-97
references.pmid: 22362824
references.citation: J Clin Invest. 2009 Nov;119(11):3189-202
references.pmid: 19884662
references.citation: Mol Cell Endocrinol. 2008 May 14;286(1-2):192-8
references.pmid: 18191325
references.citation: Pituitary. 2016 Apr;19(2):210-21
references.pmid: 26290466
references.citation: J Clin Endocrinol Metab. 2004 Feb;89(2):667-74
references.pmid: 14764779
references.citation: J Clin Endocrinol Metab. 2004 Apr;89(4):1613-7
references.pmid: 15070920
references.citation: Pituitary. 2015 Jun;18(3):385-94
references.pmid: 25103549
references.citation: Expert Opin Emerg Drugs. 2014 Mar;19(1):79-97
references.pmid: 24400774
references.citation: Endocrinol Metab Clin North Am. 2015 Mar;44(1):35-41
references.pmid: 25732640
references.citation: Eur J Endocrinol. 2012 Feb;166(2):223-34
references.pmid: 22065857
references.citation: Eur J Nucl Med. 2001 Jul;28(7):836-46
references.pmid: 11504080
references.citation: Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84
references.pmid: 25260838
references.citation: Acta Neuropathol. 1980;52(3):231-4
references.pmid: 7445985
references.citation: Nat Rev Endocrinol. 2014 Apr;10(4):243-8
references.pmid: 24566817
references.citation: Cancer Treat Res. 1997;89:1-24
references.pmid: 9204185
references.citation: Eur J Endocrinol. 2002 May;146(5):707-16
references.pmid: 11980628
references.citation: J Clin Endocrinol Metab. 2014 Mar;99(3):791-9
references.pmid: 24423324
references.citation: Endocr Pract. 2014 Oct;20 Suppl 1:7-17; quiz 18-20
references.pmid: 25374336
references.citation: J Clin Invest. 2012 Sep;122(9):3295-306
references.pmid: 22850878
references.citation: Pituitary. 2013 Dec;16(4):490-8
references.pmid: 23184260
references.citation: Neuroendocrinology. 2016;103(1):75-85
references.pmid: 26227953
references.citation: J Clin Pharmacol. 2012 Apr;52(4):552-8
references.pmid: 22282526
references.citation: N Engl J Med. 2014 Dec 18;371(25):2363-74
references.pmid: 25470569
references.citation: Endocr Rev. 2003 Feb;24(1):28-47
references.pmid: 12588807
references.citation: Rev Endocr Metab Disord. 2005 Jan;6(1):29-37
references.pmid: 15711912
references.citation: Endocr Pract. 2015 Jun;21(6):668-73
references.pmid: 26135961
references.citation: Pituitary. 2011 Jun;14(2):184-93
references.pmid: 21161602
references.citation: Pituitary. 2015 Aug;18(4):568-74
references.pmid: 25052731
references.citation: J Clin Endocrinol Metab. 2009 Feb;94(2):654-61
references.pmid: 19001514
references.citation: Eur J Endocrinol. 2008 Aug;159(2):89-95
references.pmid: 18524797
references.citation: N Engl J Med. 1996 Jan 25;334(4):246-54
references.pmid: 8532003
references.citation: J Clin Endocrinol Metab. 1984 May;58(5):796-803
references.pmid: 6423659
references.citation: J Endocrinol Invest. 2013 Jan;36(1):38-43
references.pmid: 22472799
references.citation: J Clin Endocrinol Metab. 2015 Apr;100(4):1699-708
references.pmid: 25664604
references.citation: Minerva Endocrinol. 2016 Sep;41(3):351-65
references.pmid: 26485036
references.citation: J Endocrinol Invest. 2001 Jun;24(6):430-7
references.pmid: 11434667
references.citation: J Clin Endocrinol Metab. 2013 Dec;98(12):E1918-26
references.pmid: 24152687
references.citation: Am J Ther. 2014 May-Jun;21(3):164-73
references.pmid: 22713526
references.citation: J Clin Endocrinol Metab. 2011 Sep;96(9):2732-40
references.pmid: 21715544
references.citation: Drugs. 2015 Jun;75(9):1039-48
references.pmid: 26017304
references.citation: Pituitary. 2001 Sep;4(4):239-49
references.pmid: 12501974
references.citation: J Clin Endocrinol Metab. 2003 Sep;88(9):4239-45
references.pmid: 12970293
references.citation: Discov Med. 2014 Jun;17(96):329-38
references.pmid: 24979253
references.citation: Clin Endocrinol (Oxf). 2013 Feb;78(2):263-70
references.pmid: 22783815
references.citation: Mol Endocrinol. 2011 May;25(5):859-66
references.pmid: 21330405
references.citation: Mol Cell Biol. 2000 Aug;20(16):5974-85
references.pmid: 10913180
references.citation: J Clin Endocrinol Metab. 1998 Aug;83(8):2730-4
references.pmid: 9709939
references.citation: Endocr Relat Cancer. 2015 Jun;22(3):353-67
references.pmid: 25712922
references.citation: N Engl J Med. 2000 Jun 22;342(25):1871-6
references.pmid: 10861322
references.citation: Diabetes Res Clin Pract. 2014 Mar;103(3):458-65
references.pmid: 24461109
references.citation: N Engl J Med. 2006 Dec 14;355(24):2558-73
references.pmid: 17167139
references.citation: Pituitary. 2014 Apr;17(2):180-6
references.pmid: 23564338
references.citation: Mol Cell Endocrinol. 2010 Sep 15;326(1-2):60-5
references.pmid: 20117169
references.citation: N Engl J Med. 1985 Jan 3;312(1):9-17
references.pmid: 2981107
references.citation: J Clin Endocrinol Metab. 2015 Jan;100(1):122-31
references.pmid: 25250634
references.citation: Eur J Endocrinol. 2004 Oct;151(4):439-46
references.pmid: 15476442
references.citation: Eur J Endocrinol. 2007 Jan;156(1):65-74
references.pmid: 17218727
references.citation: J Endocrinol. 2014 Nov;223(2):R19-39
references.pmid: 25134660
references.citation: Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82
references.pmid: 19650784
references.citation: Nat Rev Endocrinol. 2014 Dec;10(12):708-10
references.pmid: 25365921